ENOV Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -125.38% compared to Enovis's net margin of 4.03%. Enovis's return on equity of -25.93% beat Globus Medical's return on equity of 2.56%.

Enovis has a consensus price target of $64.20, signalling upside risk potential of 87.94%. On the other hand Globus Medical has an analysts' consensus of $97.46 which suggests that it could grow by 38.24%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $561M, which are smaller than Globus Medical quarterly revenues of $657.3M. Enovis's net income of -$703.3M is lower than Globus Medical's net income of $26.5M. Notably, Enovis's price-to-earnings ratio is -- while Globus Medical's PE ratio is 94.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.90x versus 3.85x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -125.38% compared to Enovis's net margin of -5.14%. Enovis's return on equity of -25.93% beat Integer Holdings's return on equity of 4.85%.

Enovis has a consensus price target of $64.20, signalling upside risk potential of 87.94%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 26.88%. Given that Enovis has higher upside potential than Integer Holdings, analysts believe Enovis is more attractive than Integer Holdings.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $561M, which are larger than Integer Holdings quarterly revenues of $437.4M. Enovis's net income of -$703.3M is lower than Integer Holdings's net income of -$22.5M. Notably, Enovis's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 55.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.90x versus 2.35x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -125.38% compared to Enovis's net margin of -1226.82%. Enovis's return on equity of -25.93% beat VolitionRX's return on equity of --.

Enovis has a consensus price target of $64.20, signalling upside risk potential of 87.94%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 484.68%. Given that VolitionRX has higher upside potential than Enovis, analysts believe VolitionRX is more attractive than Enovis.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $561M, which are larger than VolitionRX quarterly revenues of $474.5K. Enovis's net income of -$703.3M is lower than VolitionRX's net income of -$5.8M. Notably, Enovis's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.90x versus 35.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -125.38% compared to Enovis's net margin of -10.04%. Enovis's return on equity of -25.93% beat Xtant Medical Holdings's return on equity of -35.34%.

Enovis has a consensus price target of $64.20, signalling upside risk potential of 87.94%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 248.33%. Given that Xtant Medical Holdings has higher upside potential than Enovis, analysts believe Xtant Medical Holdings is more attractive than Enovis.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $561M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Enovis's net income of -$703.3M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Enovis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.90x versus 0.57x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.